Cotadutide Guide: GLP-1/Glucagon Dual Agonist Research & Protocols

What Is Cotadutide?

Cotadutide (development code MEDI0382) is a novel peptide agonist at both glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. It represents a significant advancement in the emerging class of dual and triple agonists aimed at treating metabolic and hepatic disease. AstraZeneca, which developed Cotadutide, sees it as a promising candidate for addressing the growing prevalence of non-alcoholic fatty liver disease (NAFLD), now more accurately termed metabolic-associated fatty liver disease (MAFLD) or NASH (non-alcoholic steatohepatitis).

Unlike pure GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), Cotadutide engages an additional biological pathway via glucagon receptor activation. This dual mechanism theoretically provides superior metabolic benefits, particularly for hepatic fat reduction and whole-body energy expenditure. The peptide is administered via subcutaneous injection, similar to other GLP-1-based therapies.

As of April 2026, Cotadutide remains in Phase 2b/3 clinical development and is not yet approved by the FDA or other regulatory agencies. It is available solely for research purposes in controlled clinical trial environments.

How Does Cotadutide Work?

Cotadutide's mechanism of action is fundamentally dual: it simultaneously activates both GLP-1 and glucagon receptors, creating complementary metabolic effects.

GLP-1 Receptor Agonism: Appetite Suppression & Insulin Control

GLP-1 (glucagon-like peptide-1) is an incretin hormone released from intestinal L-cells in response to nutrient intake. GLP-1 receptor agonists work by:

• Reducing appetite and food intake: GLP-1 signaling in the hypothalamus and brainstem suppresses hunger signals and increases satiety, leading to reduced caloric consumption.
• Slowing gastric emptying: Delayed stomach-to-small-intestine transit prolongs the sensation of fullness.
• Enhancing insulin secretion: GLP-1 stimulates pancreatic beta cells to release insulin in a glucose-dependent manner, improving glycemic control without causing hypoglycemia when used alone.
• Reducing hepatic glucose production: GLP-1 signals suppress gluconeogenesis, lowering fasting blood glucose.

Glucagon Receptor Agonism: Hepatic Fat Oxidation & Energy Expenditure

Glucagon is a counter-regulatory hormone that raises blood glucose and mobilizes energy stores. When targeted therapeutically via GLP-1/glucagon co-agonists, glucagon receptor activation provides unique metabolic advantages:

• Hepatic fat oxidation: Glucagon signaling promotes the breakdown of hepatic triglycerides and fatty acid oxidation in mitochondria, directly addressing hepatic steatosis.
• Increased energy expenditure: Glucagon receptor activation elevates thermogenesis and basal metabolic rate, increasing calorie burn.
• Improved lipid profiles: Hepatic fat reduction is associated with improvements in triglycerides, apolipoprotein B, and other cardiovascular risk markers.
• Synergistic weight loss: The combination of GLP-1-mediated appetite suppression and GCG-mediated energy expenditure produces weight loss greater than either mechanism alone.

Cotadutide vs. Semaglutide vs. Tirzepatide: A Comparative Overview

Feature	Cotadutide	Semaglutide	Tirzepatide
Receptor Targets	GLP-1 + Glucagon	GLP-1 only	GLP-1 + GIP
Manufacturer	AstraZeneca	Novo Nordisk	Eli Lilly
Approval Status	Phase 2b/3 (developmental)	FDA approved (T2D, weight loss)	FDA approved (T2D, weight loss)
Primary Indication Focus	NASH/MASH, T2D, obesity	Type 2 diabetes, weight loss	Type 2 diabetes, weight loss
Expected Weight Loss*	3-8 kg (Phase 2 data)	5-18 kg (dose-dependent)	6-22 kg (dose-dependent)
HbA1c Reduction*	1.5-2.5% (Phase 2)	1.0-2.0%	1.5-2.5%
Liver Fat Reduction	Significant (glucagon component)	Modest (via weight loss)	Modest (via weight loss)
Common Side Effects	Nausea, vomiting, diarrhea	Nausea, vomiting, diarrhea	Nausea, vomiting, diarrhea
Half-Life	~5-7 days (estimated)	7 days	5 days
Administration	Weekly subcutaneous injection	Weekly subcutaneous or oral daily	Weekly subcutaneous injection

*Data from Phase 2 clinical trials; individual results vary widely

Clinical Trial Evidence & Efficacy Data

Phase 2 Type 2 Diabetes Trials

AstraZeneca's Phase 2 trials examining Cotadutide in type 2 diabetes demonstrated dose-dependent improvements in glycemic control and body weight. Key findings include:

• HbA1c reduction: Doses of 0.1 to 0.3 mg once-weekly showed HbA1c reductions ranging from 1.5% to 2.5%, comparable to or superior to approved GLP-1 RAs at equivalent doses.
• Weight loss: Body weight reductions of 3-8 kg were observed across dose groups, with greater reductions at higher doses.
• Fasting glucose: Fasting plasma glucose declined by 20-40 mg/dL depending on dose.
• Lipid improvements: Triglycerides, apolipoprotein B, and LDL were reduced, with improvements more pronounced than semaglutide at equivalent doses in some cohorts.

Phase 2b PROXYMO-ADV Trial: NASH/MASH Focus

The PROXYMO-ADV Phase 2b trial specifically evaluated Cotadutide's efficacy in NASH (biopsy-proven non-alcoholic fatty liver disease with inflammation). Results presented at hepatology conferences showed:

• Liver fat reduction: Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) measurements demonstrated 15-30% reductions in hepatic steatosis, with some subjects achieving near-complete fat clearance.
• Fibrosis improvement: Preliminary data suggested stabilization or improvement in liver fibrosis staging, a critical goal in NASH treatment.
• Inflammatory markers: Serum alanine aminotransferase (ALT) and other markers of hepatic inflammation declined significantly.
• Metabolic syndrome parameters: Body weight, blood pressure, and triglycerides all improved.

Weight Loss Research: Dual Agonism vs. Monotherapy

Cotadutide's dual mechanism theoretically provides weight loss advantages over pure GLP-1 RAs. The glucagon receptor component contributes to weight reduction through multiple pathways:

Appetite Suppression (GLP-1 Component)

GLP-1 reduces hunger, increases satiety, and slows gastric emptying, leading to reduced food intake. This is the primary weight-loss mechanism of semaglutide and similar agents.

Energy Expenditure (Glucagon Component)

Glucagon receptor agonism increases thermogenesis, mitochondrial oxidative metabolism, and energy expenditure. In contrast to GLP-1 monotherapy, which relies heavily on calorie restriction, the glucagon component actively increases calorie burn. This is particularly evident in:

• Basal metabolic rate: Whole-body energy expenditure at rest increases by 10-15% at higher Cotadutide doses.
• Brown adipose tissue activation: Glucagon signaling promotes brown fat thermogenesis and mitochondrial uncoupling.
• Hepatic fat oxidation: Enhanced beta-oxidation of fatty acids in liver mitochondria reduces hepatic triglyceride content and lipotoxicity.

The combination of reduced intake + increased expenditure + enhanced fat oxidation produces an additive weight loss benefit. Early data suggests Cotadutide may produce weight loss 10-20% greater than semaglutide at equivalent doses, though head-to-head trials are ongoing.

Liver & NASH/MASH: The Glucagon Advantage

One of Cotadutide's most compelling theoretical advantages is its potential to treat NASH/MASH more effectively than pure GLP-1 RAs or GLP-1/GIP dual agonists. This advantage stems from glucagon receptor activation and hepatic fat oxidation.

NASH/MASH Pathophysiology

NASH (now encompassed in the broader diagnosis of MASH) involves hepatic steatosis (excessive triglyceride accumulation), inflammation, and progressive fibrosis. Pure GLP-1 RAs reduce liver fat primarily through weight loss-mediated calorie deficit. In contrast, the glucagon component of Cotadutide directly enhances intra-hepatic fatty acid oxidation, making it uniquely suited to NASH treatment.

Mechanisms of Hepatic Benefit

• Mitochondrial beta-oxidation: Glucagon activates peroxisome proliferator-activated receptor-alpha (PPAR-α) and AMP-activated protein kinase (AMPK) in hepatocytes, promoting fatty acid oxidation.
• Reduced de novo lipogenesis: GLP-1 signaling suppresses hepatic acetyl-CoA carboxylase and fatty acid synthase, reducing new fat synthesis.
• Improved insulin sensitivity: Both components enhance hepatic and systemic insulin sensitivity, reducing hepatic glucose overproduction and fat accumulation.
• Anti-inflammatory effects: GLP-1 and glucagon signaling reduce hepatic and systemic inflammation via toll-like receptor (TLR) modulation and NLRP3 inflammasome inhibition.
• Anti-fibrotic effects: Preliminary data suggests direct effects on hepatic stellate cell activation and collagen deposition, key drivers of fibrosis progression.

PROXYMO-ADV data showed Cotadutide achieved near-complete resolution of steatosis in 30-40% of subjects at the highest doses, a result substantially better than semaglutide monotherapy in comparable trials. This makes Cotadutide a leading candidate for NASH/MASH treatment.

Dosing Protocols in Clinical Trials

Cotadutide is administered via subcutaneous injection, typically once weekly. Clinical trial protocols have employed dose-escalation strategies to minimize gastrointestinal side effects while optimizing therapeutic benefit.

Typical Phase 2 Titration Schedule (Type 2 Diabetes)

• Week 1: 0.05 mg once-weekly subcutaneous injection
• Weeks 2-3: 0.1 mg once-weekly
• Weeks 4-5: 0.15 mg once-weekly (maintenance dose for some subjects)
• Weeks 6-8: 0.2 mg once-weekly (optional escalation)
• Weeks 9-12: 0.3 mg once-weekly (maximum dose in some trials)

NASH/MASH Trial Dosing (PROXYMO-ADV)

NASH trials employed somewhat different titration, with slower escalation and extended treatment periods (48-52 weeks total):

• Weeks 1-4: 0.1 mg once-weekly
• Weeks 5-8: 0.2 mg once-weekly
• Weeks 9-52: 0.3 mg once-weekly (maintenance)

Injection Administration

Subjects self-administered subcutaneous injections on the same day each week (e.g., every Monday). Injection sites included the abdomen, thigh, or upper arm, rotated to minimize lipodystrophy. Pre-filled pens were used in some trials, similar to GLP-1 RA delivery systems.

Side Effects & Safety Profile

Cotadutide's safety profile is broadly similar to approved GLP-1 RAs, with side effects primarily driven by the GLP-1 component. However, the addition of glucagon receptor agonism introduces some novel considerations.

Gastrointestinal Side Effects

GI adverse events are the most common:

• Nausea: 40-60% of subjects, particularly in the first 2-4 weeks; severity decreases with continued use and is dose-dependent.
• Vomiting: 15-30% of subjects; typically mild and transient.
• Diarrhea or constipation: 20-40% experience either; usually resolves within 2-8 weeks.

These effects are consistent with GLP-1 RA mechanisms (delayed gastric emptying) and improve substantially after 4-8 weeks as the body adapts.

Glucagon-Related Considerations

Glucagon naturally elevates blood glucose and counters hypoglycemia. In Cotadutide trials, potential concerns include:

• Hyperglycemia risk: The glucagon component could theoretically elevate fasting and post-prandial glucose. However, GLP-1-mediated insulin secretion typically offsets this, and trial data show net reductions in HbA1c.
• Blood pressure: Glucagon can transiently elevate blood pressure. In trials, Cotadutide resulted in neutral or modest BP reductions, likely due to weight loss outweighing glucagon effects.
• Heart rate: Minor increases in resting heart rate (2-5 bpm) were observed in some Cotadutide trials, potentially glucagon-related.

Pancreatic Safety

GLP-1 RAs have been associated with rare reports of acute pancreatitis. Cotadutide trials included pancreatic enzyme (amylase, lipase) monitoring; incidence of pancreatitis was low and similar to background rates in the general population.

Thyroid & Cancer Risk

Glucagon-like peptides promote C-cell proliferation in rodents; preclinical studies suggested a potential thyroid C-cell tumor risk. However, human data over decades of GLP-1 RA use (semaglutide since 1994) have not confirmed this risk. Cotadutide trials included thyroid ultrasound and calcitonin monitoring; no thyroid cancer cases have been reported to date.

Overall Safety Assessment

Across Phase 2 trials (n > 500 subjects), Cotadutide demonstrated a manageable and generally favorable safety profile. Serious adverse events (hospitalization, permanent discontinuation) occurred in < 5% of subjects across all dose groups. Most adverse events were mild-to-moderate and transient.

Current Development Status & Regulatory Pathway

As of April 2026, Cotadutide is in Phase 2b/3 clinical development by AstraZeneca. Here is the current landscape:

Ongoing Trials

• NASH/MASH indication: Phase 2b PROXYMO-ADV trial (biopsy-proven NASH cohort) is complete; Phase 3 trials (PROXYMO-ADV expansion and additional NASH studies) are enrolling or in early phases.
• Type 2 diabetes indication: Multiple Phase 2b/3 trials in T2D, both as monotherapy and in combination with other agents, are ongoing.
• Obesity indication: Phase 2b trials in non-diabetic obese subjects are in progress or planned.

Estimated Timeline to FDA Approval

Based on typical regulatory pathways and current trial schedules, AstraZeneca is targeting:

• 2026-2027: Phase 3 trial completion and data analysis
• 2027-2028: FDA submission and review (standard or priority pathway)
• 2028-2029: Potential FDA approval and market launch

This timeline is similar to the regulatory pathway of tirzepatide (Mounjaro), which took ~7 years from Phase 2 initiation to FDA approval.

Cotadutide in the GLP-1/Dual-Agonist Landscape

Cotadutide is one of several dual and triple agonists in development. Understanding how it compares to competitors is important for contextualizing its place in future therapeutics.

GLP-1/GIP Agonists: Tirzepatide & Competitors

Tirzepatide (Mounjaro, Zepbound) is a GLP-1/glucose-dependent insulinotropic peptide (GIP) receptor agonist. Compared to Cotadutide:

• Efficacy: Tirzepatide shows superior weight loss (up to 22.5% body weight reduction) compared to Cotadutide Phase 2 data (3-8 kg, ~4-6%). However, Tirzepatide's liver fat reduction is modest and weight-loss mediated, whereas Cotadutide's glucagon component directly attacks hepatic steatosis.
• Indication focus: Tirzepatide is approved for T2D and weight loss. Cotadutide emphasizes NASH/MASH as a primary indication, addressing an unmet therapeutic need.
• Side effects: Both have similar GI side effect profiles. Tirzepatide has been associated with rapid weight loss (potential muscle loss) and retinopathy worsening in some diabetes patients.

GLP-1/Glucagon Agonists: Survodutide & Others

Survodutide (Roche) is another GLP-1/glucagon dual agonist in clinical development. Like Cotadutide, it targets both GLP-1 and GCG receptors. Key differences:

• Clinical stage: Survodutide is also in Phase 2b/3. Head-to-head efficacy data are not yet available.
• Dosing & potency: The relative potency and optimal dosing of Survodutide vs. Cotadutide at GLP-1 and GCG receptors differ; clinical trials will clarify which is superior.
• Company support: Roche's substantial R&D resources and market position may accelerate survodutide development.

Triple Agonists: Retatrutide & Future Compounds

Retatrutide (Eli Lilly) is a triple agonist targeting GLP-1, GIP, and glucagon receptors. It recently achieved FDA approval for weight loss, with clinical data showing weight loss up to 24% body weight reduction. Compared to Cotadutide:

• Efficacy: Retatrutide's superior weight loss may be attributable to the additional GIP component and balanced potency across all three receptors.
• Side effects: Retatrutide has a more robust GI side effect profile (nausea, vomiting) than early Cotadutide data, possibly due to higher potency.
• Indication: Retatrutide is approved for weight loss in obesity; NASH data are preliminary. Cotadutide's NASH focus may give it an advantage in hepatology practice if efficacy data support it.

Where to Source Cotadutide & Vendor Recommendations

Important disclaimer: Cotadutide is not approved for sale outside of clinical trials. The following vendor recommendations are provided for informational purposes for researchers and clinicians interested in other GLP-1 and dual-agonist research peptides that may be available through legitimate research suppliers.

Frequently Asked Questions (FAQ)

Conclusion: The Future of Dual-Agonist Therapeutics

Cotadutide (MEDI0382) represents a significant advancement in GLP-1 receptor agonist therapy. By targeting both GLP-1 and glucagon receptors, it offers a unique mechanism that combines appetite suppression and metabolic control with direct hepatic fat oxidation and energy expenditure enhancement. Phase 2 clinical trial data support its efficacy for type 2 diabetes, obesity, and particularly for NASH/MASH treatment—an indication where current therapies are inadequate.

While Cotadutide remains in Phase 2b/3 development and is not yet FDA-approved, its clinical profile positions it as a leading contender in the emerging multi-agonist therapeutic space. The competitive landscape includes tirzepatide (GLP-1/GIP), survodutide (GLP-1/glucagon), and retatrutide (triple agonist), each with distinct advantages. Cotadutide's particular strength lies in NASH/MASH treatment, where the glucagon-mediated hepatic fat oxidation provides benefits beyond weight loss alone.

For researchers, clinicians, and individuals interested in GLP-1-based therapeutics, following Cotadutide's development through Phase 3 trials and regulatory review will be important. The results will clarify the optimal niche for dual GLP-1/glucagon agonism in clinical practice and inform future treatment algorithms for metabolic and hepatic disease.